{
  "id": 5058,
  "text": "N Engl J Med.2021.Tewari KS1, Sill MW, Long HJ 3rd, et al.Improved survival with bevacizumab in advanced cervical cancer.N Engl J Med 2014 Feb 20;370:734-743.3 Monk BJ, Sill MW, McMeekin DS, et al.Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: N Engl J Med.2021.Tewari KS1, Sill MW, Long HJ 3rd, et al.Improved survival with bevacizumab in advanced cervical cancer.N Engl J Med 2014 Feb 20;370:734-743.3 Monk BJ, Sill MW, McMeekin DS, et al.Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "研究表明，在晚期宫颈癌患者的治疗中，贝伐珠单抗（Bevacizumab）能够显著改善患者的生存率。贝伐珠单抗是一种抗血管生成药物，通过抑制血管内皮生长因子（VEGF）从而减少肿瘤血供。在晚期宫颈癌的相关临床试验中，该药物与化疗联合使用，显示了延长总体生存期的效果。因此，贝伐珠单抗已成为治疗晚期宫颈癌的一项重要选择。",
  "query": "关于宫颈癌的治疗研究中，哪种药物被表明能够改善晚期宫颈癌患者的生存率？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 关于宫颈癌的治疗研究中，哪种药物被表明能够改善晚期宫颈癌患者的生存率？\n\n<reference text>: N Engl J Med.2021.Tewari KS1, Sill MW, Long HJ 3rd, et al.Improved survival with bevacizumab in advanced cervical cancer.N Engl J Med 2014 Feb 20;370:734-743.3 Monk BJ, Sill MW, McMeekin DS, et al.Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "研究表明，在晚期宫颈癌患者的治疗中，贝伐珠单抗（Bevacizumab）能够显著改善患者的生存率。贝伐珠单抗是一种抗血管生成药物，通过抑制血管内皮生长因子（VEGF）从而减少肿瘤血供。在晚期宫颈癌的相关临床试验中，该药物与化疗联合使用，显示了延长总体生存期的效果。因此，贝伐珠单抗已成为治疗晚期宫颈癌的一项重要选择。"
}